PE20001461A1 - Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienen - Google Patents
Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienenInfo
- Publication number
- PE20001461A1 PE20001461A1 PE2000000093A PE0000932000A PE20001461A1 PE 20001461 A1 PE20001461 A1 PE 20001461A1 PE 2000000093 A PE2000000093 A PE 2000000093A PE 0000932000 A PE0000932000 A PE 0000932000A PE 20001461 A1 PE20001461 A1 PE 20001461A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- same
- halogen
- estra
- trifluoromethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical group 0.000 abstract 7
- -1 NITROXY Chemical group 0.000 abstract 6
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 5
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 4
- IBPHXKCFBXEFQP-UHFFFAOYSA-N 1,1,1,2,2-pentafluoroethane Chemical class F[C](F)C(F)(F)F IBPHXKCFBXEFQP-UHFFFAOYSA-N 0.000 abstract 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- DVMAUGGKVWJBDV-COMOZRQASA-N (8s,9s,13r,14s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC(O)C[C@@]1(C)CC2 DVMAUGGKVWJBDV-COMOZRQASA-N 0.000 abstract 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical class ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 abstract 1
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 abstract 1
- 102100037189 Sodium- and chloride-dependent transporter XTRP3 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical class [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
- 150000003462 sulfoxides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0055—Estrane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 3,16-DIHIDROXI-ESTRA-1,3,5(10)-TRIENO DE FORMULA I, DONDE: R1 ES HALOGENO, OH, METILO, TRIFLUOROMETILO, METOXI, ETOXI, H; R2 ES HALOGENO, OH, ALCOXI C1-C6, H; R4 ES HALOGENO, ALQUILO C1-C10, TRIFLUOROMETILO, PENTAFLUOROETILO, ALCOXI C1-C6, H; R7 ES HALOGENO EN POSICION O O ß, ALQUILO C1-C10, ALCOXI C1-C6, ARILO, HETEROARILO, H; R8 ES H EN POSICION O O ß, ALQUILO C1-C10, CIANO; R9 ES H EN POSICION O O ß, METILO, ETILO, TRIFLUOROMETILO, PENTAFLUOROETILO EN POSICION O O ß; R11 ES NITROXI, OH, MERCAPTO, HALOGENO, CLOROMETILO, ALQUILO C1-C10, ALCOXI, ALQUILTIO C1-C6, ARILO, HETEROARILO, H; R13 ES METILO, ETILO, TRIFLUOROMETILO, PENTAFLUOROETILO EN POSICON O O ß; R14 ES ALQUILO C1-C10 EN POSICION O O ß, H; R15 ES HALOGENO EN POSICION O O ß, ALQUILO C1-C10, SULFOXIDO, SULFONICO, IMINO, =NR15`, H; R15' ES H, METILO, ETILO PROPILO; R14 Y R15 JUNTOS SON 14O-15O-METILENO O 14ß-15ß-METILENO; R16 ES ALQUILO C1-C10, TRIFLUOROMETILO, PENTAFLUOROMETILO, CIANOMETILO, H EN POSICION O O ß; R17 ES HALOGENO, ALQUILO C1-C10, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 14O,15O-METILEN-ESTRA-1,3,5(10)-TRIEN-3,16O-DIOL, 14ß,15ß-METILEN-ESTRA-1,3,5(10)-8(9)-TETRAEN-3,16O-DIOL, ENTRE OTROS. LOS COMPUESTOS DE FORMULA I PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES CON DEFICIENCIA DE ESTROGENO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906159A DE19906159A1 (de) | 1999-02-09 | 1999-02-09 | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001461A1 true PE20001461A1 (es) | 2000-12-18 |
Family
ID=7897485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000093A PE20001461A1 (es) | 1999-02-09 | 2000-02-08 | Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienen |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP1144431B1 (es) |
| JP (1) | JP2002536455A (es) |
| KR (1) | KR20010101822A (es) |
| CN (1) | CN1346364A (es) |
| AR (1) | AR034392A1 (es) |
| AT (1) | ATE313553T1 (es) |
| AU (1) | AU2909500A (es) |
| BG (1) | BG105804A (es) |
| BR (1) | BR0008076A (es) |
| CA (1) | CA2359660A1 (es) |
| CO (1) | CO5150223A1 (es) |
| CZ (1) | CZ20012843A3 (es) |
| DE (2) | DE19906159A1 (es) |
| DK (1) | DK1144431T3 (es) |
| EA (1) | EA200100828A1 (es) |
| EE (1) | EE200100412A (es) |
| ES (1) | ES2255983T3 (es) |
| HK (1) | HK1046145A1 (es) |
| HU (1) | HUP0200055A3 (es) |
| IL (1) | IL144455A0 (es) |
| MX (1) | MXPA01008065A (es) |
| NO (1) | NO20013860L (es) |
| NZ (1) | NZ513409A (es) |
| PE (1) | PE20001461A1 (es) |
| PL (1) | PL350360A1 (es) |
| PT (1) | PT1144431E (es) |
| SK (1) | SK11302001A3 (es) |
| WO (1) | WO2000047603A2 (es) |
| YU (1) | YU57201A (es) |
| ZA (1) | ZA200107388B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10039199A1 (de) * | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| DE10048634A1 (de) * | 2000-09-27 | 2002-04-18 | Jenapharm Gmbh | 19-Nor-17alpha-pregna-1,3,5(10)-trien-17beta-ole mit einem 21, 16alpha-Laktonring |
| DE10151365A1 (de) | 2001-10-17 | 2003-04-30 | Schering Ag | 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten |
| DE10151114A1 (de) * | 2001-10-15 | 2003-04-17 | Schering Ag | 8ß-Substituierte-11ß-aryl-estra-2,3,5(10)-trienderivate |
| DE10151363A1 (de) * | 2001-10-17 | 2003-05-08 | Schering Ag | Somatotrope Therapie |
| DE10226326A1 (de) * | 2002-06-11 | 2004-01-15 | Schering Ag | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
| US7414043B2 (en) | 2002-06-11 | 2008-08-19 | Schering Ag | 9-α-substituted estratrienes as selectively active estrogens |
| TWI392682B (zh) * | 2006-04-13 | 2013-04-11 | Sigma Tau Ind Farmaceuti | 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物 |
| TWI389917B (zh) * | 2006-04-13 | 2013-03-21 | Sigma Tau Ind Farmaceuti | 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物 |
| SE536263C2 (sv) * | 2011-12-21 | 2013-07-23 | Airqone Building Scandinavia Ab | Reningsanordning för gasmedium innefattande medel för kontrollerad tillförsel av joniserad luft |
| KR20190042651A (ko) * | 2016-08-22 | 2019-04-24 | 오르-게닉스 쎄라퓨틱스, 인코포레이티드 | 에스트로겐 수용체 베타 선택적 리간드 |
| WO2019041078A1 (en) | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| US11512107B2 (en) | 2018-09-07 | 2022-11-29 | Trustees Of Dartmouth College | Methods for assembly of tetracyclic compounds by stereoselective C9-C10 bond formation |
| WO2020051329A1 (en) * | 2018-09-07 | 2020-03-12 | Trustees Of Dartmouth College | C19 scaffolds and steroids and methods of use and manufacture thereof |
| CN115154474A (zh) * | 2021-04-01 | 2022-10-11 | 中国人民解放军总医院 | 一种环菠萝蜜烷型三萜皂苷化合物在制备t细胞免疫抑制剂中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3103524A (en) * | 1963-09-10 | Ratetraene- | ||
| US3079408A (en) * | 1963-02-26 | Ig-bisoxygenated iy-haloestra- | ||
| GB823955A (en) * | 1955-09-01 | 1959-11-18 | Nepera Chemical Co Inc | Improvements in steroid compounds and method for manufacture of same |
| GB804789A (en) * | 1956-02-06 | 1958-11-26 | Searle & Co | 16-alkylestratriene-3,16,17-triols and derivatives thereof |
| US2779773A (en) * | 1956-05-23 | 1957-01-29 | Nepera Chemical Co Inc | Steroid 3, 16alpha-diols and process |
| US3166473A (en) * | 1962-04-12 | 1965-01-19 | Mochida Pharm Co Ltd | New esters of 1, 3, 5-estratriene-3, 16, 17-triol and novel pharmaceutical compositions containing new esters of 1, 3, 5-estratriene-3, 16, 17-triol and esters of 1, 3, 5-estratriene-3, 16, 17-triol |
| NL124324C (es) * | 1964-01-24 | |||
| FR4339M (es) * | 1965-03-29 | 1966-08-08 | ||
| FR5099M (es) * | 1966-01-12 | 1967-05-22 | ||
| US3449383A (en) * | 1967-02-16 | 1969-06-10 | Searle & Co | 17-oxygenated estra-1,3,5(10)-triene-3,11beta,16-triols,ethers and esters thereof |
| US3470159A (en) * | 1967-07-13 | 1969-09-30 | American Home Prod | Estra-1,3,5(10),7-tetraenes and process of preparation |
| GB1235642A (en) * | 1969-02-27 | 1971-06-16 | Ciba Geigy | A new oestratriol and a process for its manufacture |
| CH538460A (de) * | 1969-02-27 | 1973-06-30 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen hochwirksamen Östratriols |
| FR2034569B1 (es) * | 1969-02-27 | 1973-07-13 | Ciba Geigy Ag | |
| CH537916A (de) * | 1969-02-27 | 1973-06-15 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen Östratriols |
| US3600705A (en) * | 1969-02-27 | 1971-08-17 | Gen Electric | Highly efficient subcritically doped electron-transfer effect devices |
| US3622670A (en) * | 1969-08-22 | 1971-11-23 | American Home Prod | Method of inducing ovulation |
| IL38806A0 (en) * | 1971-03-05 | 1972-04-27 | Ciba Geigy Ag | Pharmaceutical compositions comprising estrogens and anthracene derivatives |
| US3766224A (en) * | 1971-06-03 | 1973-10-16 | Sandoz Ag | 15-methyl-substituted steroids |
| US3946052A (en) * | 1975-06-16 | 1976-03-23 | Stanford Research Institute | 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity |
| JPS5265259A (en) * | 1975-11-27 | 1977-05-30 | Takeda Chem Ind Ltd | Synthesis of 16beta-alkylestradiol or its 17-esters |
| NL7613248A (nl) * | 1976-11-26 | 1978-05-30 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroid- esters. |
| DD145919B1 (de) * | 1978-06-28 | 1982-06-30 | Kurt Ponsold | Verfahren zur herstellung von 14,1 -methylenderivaten der oestranreihe |
| SE8305596D0 (sv) * | 1983-10-12 | 1983-10-12 | Leo Ab | A selective acylation method |
| DE3510555A1 (de) * | 1985-03-21 | 1986-09-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Estriolester |
| US4705783A (en) * | 1985-06-25 | 1987-11-10 | Sri International | 9α, 11β-substituted and 11β-substituted estranes |
| HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
| SU1761760A1 (ru) * | 1990-07-02 | 1992-09-15 | Всесоюзный Эндокринологический Научный Центр Амн Ссср | Способ получени 11-нитратов 9 @ , 11 @ -диоксистероидов |
| DE4239946C2 (de) * | 1992-11-27 | 2001-09-13 | Jenapharm Gmbh | Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung |
| DE4322186A1 (de) * | 1993-07-03 | 1995-01-12 | Jenapharm Gmbh | Oral estrogen wirksame Ester des 14alpha, 15alpha-Methylen-estradiols |
| DE4326240A1 (de) * | 1993-08-02 | 1995-02-09 | Schering Ag | 15,15-Dialkyl-substituierte Derivate des Estradiols |
| US5554603A (en) * | 1993-09-17 | 1996-09-10 | The United States Of America As Represented By The Department Of Health And Human Services | Orally active derivatives of 1,3,5(10)-estratriene |
| DE4338314C1 (de) * | 1993-11-10 | 1995-03-30 | Jenapharm Gmbh | Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen |
| SE9502921D0 (sv) * | 1995-08-23 | 1995-08-23 | Astra Ab | New compounds |
| DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE19815060A1 (de) * | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
-
1999
- 1999-02-09 DE DE19906159A patent/DE19906159A1/de not_active Withdrawn
-
2000
- 2000-02-08 PE PE2000000093A patent/PE20001461A1/es not_active Application Discontinuation
- 2000-02-08 CO CO00007990A patent/CO5150223A1/es unknown
- 2000-02-09 ES ES00907539T patent/ES2255983T3/es not_active Expired - Lifetime
- 2000-02-09 EP EP00907539A patent/EP1144431B1/de not_active Expired - Lifetime
- 2000-02-09 CA CA002359660A patent/CA2359660A1/en not_active Abandoned
- 2000-02-09 WO PCT/EP2000/001073 patent/WO2000047603A2/de not_active Ceased
- 2000-02-09 HK HK02107553.2A patent/HK1046145A1/zh unknown
- 2000-02-09 NZ NZ513409A patent/NZ513409A/xx unknown
- 2000-02-09 YU YU57201A patent/YU57201A/sh unknown
- 2000-02-09 IL IL14445500A patent/IL144455A0/xx unknown
- 2000-02-09 DE DE50011908T patent/DE50011908D1/de not_active Expired - Fee Related
- 2000-02-09 CN CN00803613A patent/CN1346364A/zh active Pending
- 2000-02-09 CZ CZ20012843A patent/CZ20012843A3/cs unknown
- 2000-02-09 KR KR1020017009989A patent/KR20010101822A/ko not_active Withdrawn
- 2000-02-09 EE EEP200100412A patent/EE200100412A/xx unknown
- 2000-02-09 PL PL00350360A patent/PL350360A1/xx not_active Application Discontinuation
- 2000-02-09 EA EA200100828A patent/EA200100828A1/ru unknown
- 2000-02-09 AU AU29095/00A patent/AU2909500A/en not_active Abandoned
- 2000-02-09 EP EP05075149A patent/EP1580192A2/de not_active Withdrawn
- 2000-02-09 HU HU0200055A patent/HUP0200055A3/hu unknown
- 2000-02-09 BR BR0008076-4A patent/BR0008076A/pt not_active IP Right Cessation
- 2000-02-09 MX MXPA01008065A patent/MXPA01008065A/es unknown
- 2000-02-09 AR ARP000100553A patent/AR034392A1/es not_active Application Discontinuation
- 2000-02-09 JP JP2000598520A patent/JP2002536455A/ja active Pending
- 2000-02-09 AT AT00907539T patent/ATE313553T1/de not_active IP Right Cessation
- 2000-02-09 PT PT00907539T patent/PT1144431E/pt unknown
- 2000-02-09 SK SK1130-2001A patent/SK11302001A3/sk unknown
- 2000-02-09 DK DK00907539T patent/DK1144431T3/da active
-
2001
- 2001-08-08 NO NO20013860A patent/NO20013860L/no not_active Application Discontinuation
- 2001-08-09 BG BG105804A patent/BG105804A/xx unknown
- 2001-09-06 ZA ZA200107388A patent/ZA200107388B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20001461A1 (es) | Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienen | |
| PE20010543A1 (es) | Derivados de purina como inhibidores de tirosincinasa syk | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| PE20011066A1 (es) | PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS | |
| AR008327A1 (es) | Aminoguanidinas y alcoxiguanidinas como inhibidores de proteasa, alcoxiaminas para su exclusivo uso en el procedimiento de obtencion de dichos compuestos, composicion farmaceutica, uso de dichos compuestos y composiciones para preparar medicamentos, dispositivo usado en la recolección, circulacion y almacenamiento de sangre y proceso para preparar dichos compuestos. | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| PE20010930A1 (es) | Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales | |
| PE20020473A1 (es) | USO COMBINADO DE INHIBIDORES DE ACETILCOLINESTERASA Y AGONISTAS INVERSOS DE GABAa PARA EL TRATAMIENTO DE TRASTORNOS COGNITIVOS | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| AR035548A1 (es) | Compuestos organicos | |
| JP2003502369A5 (es) | ||
| CY1110951T1 (el) | Αζαϊνδολες | |
| PE79999A1 (es) | Derivados de macrolidos c-4" sustituidos | |
| HRP20020175B1 (hr) | N-heterociklički derivati kao inhibitori nos | |
| RU2002107975A (ru) | Глюкопиранозилоксипиразольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для их получения | |
| CA2286723A1 (en) | Tricyclic compounds | |
| PE20040772A1 (es) | Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos | |
| PE20021004A1 (es) | Derivados de piperidina como inhibidores de la ccr5 | |
| NO983493L (no) | Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike | |
| PE20001289A1 (es) | Nuevos antibioticos macrolidos | |
| PE20040907A1 (es) | Derivados de anilinopirazol | |
| DK1189900T3 (da) | Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler | |
| NO20003773L (no) | Syklobutenderivater, deres fremstilling og deres terapeutiske anvendelser | |
| CO5580825A2 (es) | Derivados heterociclicos de glicinamida y su uso medico | |
| PE20020599A1 (es) | Derivados de acido amino-furan-2-il-acetico sustituido o de acido amino-tien-2-il-acetico sustituido, procedimiento para su preparacion, medicamentos que los contienen, uso de estos compuestos para la preparacion de medicamentos para el tratamiento d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |